Table 3. Uni- and multivariate Cox cause-specific hazards analysis of pRCC, ccRCC, and pRCC subtypes (type 1 and type 2) and clinical/ pathological variables for the prediction of cancer-specific mortality in patients with non-metastatic and metastatic RCC.

	Univariate analysis			Multivariate analysis
	HR	95%CI	p	HR	95%CI	p
Patients with non-metastatic disease (M0)
Age	1.02	1.01–1.03	<0.001	1.02*	1.01–1.03	<0.001
Sex (Female vs. Male)	0.74	0.63–0.87	<0.001	0.73*	0.62–0.86	<0.001
pT (pT 3–4 vs. pT 1–2)	4.16	3.57–4.85	<0.001	3.19*	2.73–3.74	<0.001
Grade (G 3–4 vs. G 1–2)	4.78	4.1–5.57	<0.001	3.75*	3.21–4.38	<0.001
pRCC vs. ccRCC	0.61	0.5–0.75	<0.001	0.76	0.62–0.93	0.007
pRCC type 2 vs. type1	4.59	1.31–16.11	0.017	2.9	0.83–10.19	0.097
pRCC type 1 vs. ccRCC	0.2	0.06–0.62	0.005	0.31	0.1–0.97	0.044
pRCC type 2 vs. ccRCC	0.91	0.52–1.57	0.722	0.9	0.52–1.57	0.722
Patients with metastatic disease (M1)
Age	1	0.99–1.01	0.753	1*	1–1.01	0.304
Sex (Female vs. Male)	0.9	0.75–1.08	0.266	0.87*	0.72–1.05	0.135
pT (pT 3–4 vs. pT 1–2)	1.44	1.2–1.73	<0.001	1.4*	1.16–1.69	<0.001
Grade (G 3–4 vs. G 1–2)	1.49	1.26–1.77	<0.001	1.46*	1.22–1.73	<0.001
pRCC vs. ccRCC	0.85	0.7–1.04	0.108	0.82	0.67–1	0.05
pRCC type 2 vs. type1	4.39	1.04–18.61	0.045	3.51	0.83–14.85	0.088
pRCC type 1 vs. ccRCC	0.24	0.06–0.97	0.046	0.29	0.07–1.16	0.079
pRCC type 2 vs. ccRCC	1.02	0.68–1.52	0.933	1.01	0.67–1.52	0.957

* HRs are based on two different Cox models and therefore might slightly differ